<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01863186</url>
  </required_header>
  <id_info>
    <org_study_id>USWM-LX1-3003-1</org_study_id>
    <secondary_id>1U01DA033276-01A1</secondary_id>
    <nct_id>NCT01863186</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal</brief_title>
  <official_title>Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US WorldMeds LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>US WorldMeds LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at the efficacy and safety for lofexidine hydrochloride,&#xD;
      an alpha-2 adrenergic agonist under development for the treatment of acute withdrawal from&#xD;
      short-acting opioids. The study takes place in 2 parts: a 7-day inpatient double-blind&#xD;
      treatment portion where subjects will be randomly assigned to one of three doses of study&#xD;
      medication (2.4 mg total daily dose of lofexidine, 3.2 mg total daily dose of lofexidine, or&#xD;
      placebo) followed by an optional open-label treatment period where subjects will be inpatient&#xD;
      or outpatient and receive lofexidine at variable dosing for up to an additional 7 days. The&#xD;
      Investigator hypothesizes that subjects will achieve maximum treatment effect with tolerable&#xD;
      side effects at the 3.2 mg total daily dose and that both the 3.2 mg and 2.4 total daily&#xD;
      doses will show better efficacy over placebo in treating symptoms of acute opioid withdrawal.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, two-part, multicenter study to evaluate the dose-response, efficacy, and&#xD;
      safety of lofexidine in alleviation of symptoms in subjects undergoing total and abrupt&#xD;
      withdrawal from short-acting opioids. Any subject dependent on short-acting opioids (the&#xD;
      primary projected indication for lofexidine) about to undergo opioid withdrawal will be&#xD;
      eligible. Subjects will be evaluated for their compliance with protocol inclusion/exclusion&#xD;
      criteria during a screening period, lasting up to 7 days.&#xD;
&#xD;
      The first part of the study will use an inpatient, randomized, double-blind, and&#xD;
      placebo-controlled design (Days 1-7) followed by a second part, an open-label continuation&#xD;
      treatment (Days 8-14). A total of 600 subjects will be randomized to receive lofexidine 2.4&#xD;
      mg total daily dose (0.6 mg QID), lofexidine 3.2 mg total daily dose (0.8 mg QID), or&#xD;
      matching placebo in a 3:3:2 ratio (225:225:150) for 7 days (i.e., during the most intense&#xD;
      stage of withdrawal). During the second part of the study (Days 8-14), all subjects,&#xD;
      regardless of their treatment assignment (which will remain double-blinded), who successfully&#xD;
      meet the definition for &quot;completer&quot; based on Days 1-7 (i.e., receives at least one dose of&#xD;
      study medication on Day 7 and completes the 3.5-hour post-dose SOWS-Gossop assessment on Day&#xD;
      7), will be eligible to receive open-label, variable dose lofexidine treatment (as determined&#xD;
      by the Site Investigator, but not to exceed 3.2 mg/day) for up to an additional 7 days in&#xD;
      either an inpatient or outpatient setting depending on the wishes of the investigator and the&#xD;
      subject. No subject will receive lofexidine for more than 14 days total from the onset of&#xD;
      abstinence. There will be no initial dose run-up and no mandated terminal dose taper.&#xD;
&#xD;
      Efficacy and safety assessments will be made daily throughout the study. Safety will be&#xD;
      assessed by evaluation of adverse event, clinical labs, electrocardiograms (with special&#xD;
      attention to QTc), vital signs, physical exam data, and the Columbia-Suicide Severity Rating&#xD;
      Scale. Efficacy will be evaluated daily by subject- and observer-completed scales including&#xD;
      the Short Opiate Withdrawal Scale of Gossop (SOWS-G)(the primary outcome measure is SOWS-G&#xD;
      score area under the curve for Days 1-7), the Clinical Opiate Withdrawal Scales (COWS),&#xD;
      Objective Opiate Withdrawal Scale (OOWS-Handelsman), the Visual Analog Scale for Efficacy&#xD;
      (VAS-E), and the Modified Clinical Global Impressions scales for efficacy and side effects.&#xD;
      Efficacy will also be evaluated by study retention, completion rates, concomitant medication&#xD;
      use, incidence of withdrawal-related Adverse Events (AEs), and subject treatment status 30&#xD;
      days post last dose of study medication. Qualitative urine drug screening will be done every&#xD;
      other day to monitor for contraband (inpatient setting) or illicit (outpatient setting) drug&#xD;
      use. Upon a subject's exit from the study, Study Discontinuation/End of Study assessments&#xD;
      will be done.&#xD;
&#xD;
      During the study, study drug compliance will be documented in the source daily. During the&#xD;
      first part of the study (Days 1-7), subjects will be inpatient and each dose of study&#xD;
      medication will be administered by study site personnel and recorded in the source. Study&#xD;
      medication will be dosed QID at 8 AM, 1 PM, 6 PM and 11 PM. During the second part of the&#xD;
      study (Days 8-14), subjects who remain inpatient will be administered each dose of study&#xD;
      medication by study site personnel and dosing will be captured in the source. Subjects who&#xD;
      complete the second part of the study on an outpatient basis will return to the clinic daily&#xD;
      for study assessments. During the open-label period, subjects will be dispensed 1-2 days&#xD;
      worth of study drug, as needed to allow for flexibility in scheduling daily visits, to get&#xD;
      them through until they are supposed to return the following day for additional study&#xD;
      assessments and dosing.&#xD;
&#xD;
      Study medication will be held if vital signs meet any of the following criteria: Resting&#xD;
      (sitting or recumbent, if required, for treatment of an adverse event): Systolic blood&#xD;
      pressure &lt;90 mmHg and &gt;20% below screen value; Diastolic blood pressure &lt;50 mmHg and &gt;20%&#xD;
      below screen value; Heart rate &lt;50 bpm and &gt;20% below screen value; and Symptoms of&#xD;
      hypotension and/or bradycardia (e.g., lightheadedness, dizziness, syncope).Orthostatic (after&#xD;
      standing for 3 minutes): Systolic blood pressure diastolic blood pressure, or pulse &gt;25%&#xD;
      below recumbent values.&#xD;
&#xD;
      A subject will be discontinued from the study if any of the following criteria are met:&#xD;
      Systolic blood pressure &lt;70 mmHg and &gt;20% below screen value; Diastolic blood pressure &lt;40&#xD;
      mmHg and &gt;20% below screen value; Heart rate &lt;40 bpm and &gt;20% below screen value; QTc &gt;500&#xD;
      msec or &gt;25% above screen value for both males and females; Syncope; Subject misses more than&#xD;
      2 doses in 24 hours during Days 1-7 prior to meeting &quot;completer&quot; criteria (i.e., receives at&#xD;
      least one dose of study medication on Day 7 and completed the 3.5-hour post-dose SOWS-Gossop&#xD;
      assessments on Day 7); Subject misses a total of 6 doses during Days 1-7 prior to meeting&#xD;
      &quot;completer&quot; criteria (i.e., receives at least one dose of study medication on Day 7 and&#xD;
      completed the 3.5-hour post-dose SOWS-Gossop assessments on Day 7); Concomitant medication&#xD;
      use (other than alumina, magnesia, and simethicone) for intolerable nausea and emesis.&#xD;
&#xD;
      Subjects should be discontinued from the study for any of the reasons listed below, and the&#xD;
      event should be recorded as an Adverse Event (AE) and the subject followed until medically&#xD;
      stabilized to the satisfaction of the attending physician: New onset of clinically&#xD;
      significant abnormal ECG (e.g., second or third degree heart block or uncontrolled&#xD;
      arrhythmia, prolonged QTcF interval); Persistent symptomatic hypotension (e.g., hypotension&#xD;
      not responding to bed rest or fluids); Single occurrence of symptomatic bradycardia (as&#xD;
      assessed by the Investigator, regardless of blood pressure) associated with chest pain,&#xD;
      shortness of breath, or decreased level of consciousness; Persistent hypertension - blood&#xD;
      pressure ≥185/110 mmHg recorded on 3 separate occasions taken at least 5 minutes apart AND&#xD;
      within a 1-hour time period. If all 3 readings are ≥185/110 mmHg (either systolic ≥185 mmHg&#xD;
      or diastolic ≥110 mmHg) the subject must be terminated; Medical Intervention for&#xD;
      Cardiovascular Event: Any medical intervention (nonmedication or medication inclusive) used&#xD;
      for the treatment of any cardiovascular event, with the exception of a positional&#xD;
      intervention in subjects displaying hypotension; Any other clinically significant&#xD;
      cardiovascular signs or symptoms that would place the subject at risk.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference Between the Overall Means From Short Opiate Withdrawal Scale of Gossop (SOWS-Gossop) Scores</measure>
    <time_frame>Days 1 through 7</time_frame>
    <description>The SOWS-Gossop was completed by the mITT population subject at baseline, once daily at 3.5 hours after the first dose of the study medication on Days 1 to 7. It consists of 10 items that are scored on a 4-point scale; 0=none, 1=mild, 2=moderate, and 3=severe. The overall score is the simple sum of the 10-item scores (minimum overall score of 0, maximum score of 30). Higher individual scores on the scale indicate greater symptom severity. However, as the outcome measure is a difference from placebo, a lower number indicates a better outcome.&#xD;
mITT population: all randomized subjects who received at least 1 dose of study medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Completion Status</measure>
    <time_frame>Day 7</time_frame>
    <description>The percentage of subjects in each treatment arm who receive at least one dose of study medication on Day 7 and complete the 3.5 hour post-dose SOWS-Gossop assessment on Day 7.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">603</enrollment>
  <condition>Opioid Dependence</condition>
  <condition>Acute Opioid Withdrawal Syndrome</condition>
  <arm_group>
    <arm_group_label>Lofexidine HCl (2.4mg dose)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>225 subjects will be randomized to receive 2.4 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 2.4 mg (one tablet in each dose will be a placebo tablet to maintain the blind) for up to 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lofexidine HCl (3.2mg dose)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>225 subjects will be randomized to receive 3.2 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 3.2 mg for up to 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>150 subjects will be randomized to receive placebo during the double-blind period of the study. Subjects will take 4 tablets QID for up to 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open Label Lofexidine HCl</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>During the open-label portion of the study, subjects will be given the option to receive lofexidine HCl tablets for up to 7 days. Dosing regimens are at the discretion of the Investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lofexidine HCl</intervention_name>
    <description>Lofexidine HCl tablets will be available in 0.2 mg tablets. Lofexidine will be provided in total daily doses as indicated during the double blind portion of the study.</description>
    <arm_group_label>Lofexidine HCl (2.4mg dose)</arm_group_label>
    <arm_group_label>Lofexidine HCl (3.2mg dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.</description>
    <arm_group_label>Lofexidine HCl (2.4mg dose)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Open Label Lofexidine HCL</intervention_name>
    <description>Lofexidine HCl tablets will are available in 0.2 mg tablets. During the optional open-label portion of the study, Lofexidine HCl can be prescribed at the discretion of the Investigator but total daily dose will not exceed 3.2 mg.</description>
    <arm_group_label>Open Label Lofexidine HCl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female at least 18 years of age.&#xD;
&#xD;
          -  Currently dependence, according to the Mini International Neuropsychiatric Interview&#xD;
             (M.I.N.I.) [17, 18], on any opioid with a half-life similar to heroin or morphine,&#xD;
             including Vicodin®, Lortab®, Lorcet®, Percocet®, Percodan®, Tylox®, or Hydrocodone (by&#xD;
             any route of administration), or oxycodone (oxycodone and oxycodone time-released&#xD;
             formulation when crushed and snorted, injected or swallowed after chewing).&#xD;
&#xD;
          -  Seeking treatment for opioid dependence.&#xD;
&#xD;
          -  Score of ≥2 on the Objective Opiate Withdrawal Scale (OOWS-Handelsman) at Baseline.&#xD;
&#xD;
          -  Reported use of heroin, morphine, or any opioid with a half-life similar to heroin or&#xD;
             morphine for at least 21 of the past 30 days.&#xD;
&#xD;
          -  Urine toxicology screen positive for opioids but negative for methadone and&#xD;
             buprenorphine.&#xD;
&#xD;
          -  Females of childbearing potential must agree to using birth control methods and must&#xD;
             have had documented proof.&#xD;
&#xD;
          -  Able to verbalize understanding of the consent form, able to provide written informed&#xD;
             consent, verbalize willingness to complete study procedures, and pass the study&#xD;
             consent quiz with 100% accuracy (if necessary, quiz may be administered more than one&#xD;
             time).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female subject who is pregnant or lactating.&#xD;
&#xD;
          -  Self-reported use of methadone or buprenorphine in the past 14 days.&#xD;
&#xD;
          -  Serious medical illnesses including, but not limited to: seizures, pancreatic disease,&#xD;
             liver disease, exposure to a hepatitis virus, and positive hepatitis results.&#xD;
&#xD;
          -  Psychiatric disorder, based on the M.I.N.I., including but not limited to dementia or&#xD;
             any disorder that, in the opinion of the study physician requires ongoing treatment&#xD;
             that would make study participation unsafe or which would make treatment compliance&#xD;
             difficult.&#xD;
&#xD;
          -  Self-reported acquired immune deficiency syndrome (AIDS) or self-reported human&#xD;
             immunodeficiency virus (HIV) positive status and taking retroviral medications&#xD;
             currently or within the past 4 weeks.&#xD;
&#xD;
          -  Abnormal cardiovascular exam at screening and before randomization, including any of&#xD;
             the following: clinically significant abnormal electrocardiogram (ECG) (e.g., second&#xD;
             or third degree heart block, uncontrolled arrhythmia, or QTcF interval greater than&#xD;
             450 msec for males and greater than 470 msec for females); heart rate less than 55 bpm&#xD;
             or symptomatic bradycardia; systolic blood pressure (SBP) less than 95 mmHg or&#xD;
             symptomatic hypotension; diastolic blood pressure (DBP) less than 65 mmHg; blood&#xD;
             pressure (BP) greater than 155/95 mmHg; and prior history of myocardial infarction.&#xD;
&#xD;
          -  Clinically significant abnormal laboratory values.&#xD;
&#xD;
          -  Requiring any of the following medications currently or within the past 4 weeks:&#xD;
             psychotropics (including sedatives/hypnotics, antidepressants, neuroleptics),&#xD;
             prescription analgesics (excluding those listed in inclusion criterion #2 above),&#xD;
             anticonvulsants, antihypertensives, antiarrhythmics, antiretroviral, and cholesterol&#xD;
             lowering medications. Nicotine replacement therapy (patch, inhaler, gum, or nasal&#xD;
             spray) will be allowed for nicotine-dependent subjects. Note: Use of a short-acting&#xD;
             benzodiazepine (e.g., oxazepam) for insomnia during Days 8 14 will not disqualify a&#xD;
             subject.&#xD;
&#xD;
          -  Currently dependent (based on the M.I.N.I.) on any psychoactive substance (other than&#xD;
             that listed in inclusion criterion #2, caffeine or nicotine) that requires&#xD;
             detoxification.&#xD;
&#xD;
          -  Donated blood within the last 8 weeks.&#xD;
&#xD;
          -  Participated in an investigational drug study within the past 3 months.&#xD;
&#xD;
          -  Has &quot;poor&quot; veins that even a single venipuncture cannot be obtained during screening.&#xD;
&#xD;
          -  Active tuberculosis (positive tuberculin test and/or confirmatory diagnostic chest&#xD;
             x-ray).&#xD;
&#xD;
          -  Active syphilis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles W Gorodetzky, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>US WorldMeds</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Clovis</city>
        <state>California</state>
        <zip>93611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oak Park</city>
        <state>Illinois</state>
        <zip>60301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70629</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 22, 2013</study_first_submitted>
  <study_first_submitted_qc>May 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2013</study_first_posted>
  <results_first_submitted>November 25, 2020</results_first_submitted>
  <results_first_submitted_qc>January 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 4, 2021</results_first_posted>
  <disposition_first_submitted>February 12, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>February 12, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 4, 2015</disposition_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lofexidine</keyword>
  <keyword>opioid dependence</keyword>
  <keyword>acute withdrawal syndrome</keyword>
  <keyword>opioid withdrawal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lofexidine</mesh_term>
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 22, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT01863186/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 6, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT01863186/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 25, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT01863186/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DB: Lofexidine HCl 2.4mg Dose</title>
          <description>Participants were randomized to receive 2.4 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 2.4 mg (one tablet in each dose will be a placebo tablet to maintain the blind) for up to 7 days.</description>
        </group>
        <group group_id="P2">
          <title>DB: Lofexidine HCl 3.2mg Dose</title>
          <description>Participants were randomized to receive 3.2 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 3.2 mg for up to 7 days.</description>
        </group>
        <group group_id="P3">
          <title>DB: Placebo</title>
          <description>Participants were randomized to receive placebo during the double-blind period of the study. Subjects will take 4 tablets QID for up to 7 days.&#xD;
Placebo: Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.</description>
        </group>
        <group group_id="P4">
          <title>OL: All Lofexidine HCl</title>
          <description>Participants were given the option to receive lofexidine HCl tablets for up to 7 additional days, following the double blind period. Dosing regimens are at the discretion of the Investigator, but total daily dose will not exceed 3.2 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="229">Original number of 230. One participant was randomly assigned into the study, but not dosed.</participants>
                <participants group_id="P2" count="222"/>
                <participants group_id="P3" count="151"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="109"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Open-label Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0">No placebo group in the Open-label Phase.</participants>
                <participants group_id="P4" count="83">36 from 2.4 mg group, 28 from 3.2mg group, and 19 from Placebo continued to the Open-label phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Demographic Characteristics of modified intent-to-treat &quot;mITT&quot; Population (excludes one subject who randomized but never received study drug)</population>
      <group_list>
        <group group_id="B1">
          <title>DB: Lofexidine HCl 2.4mg Dose</title>
          <description>Participants were randomized to receive 2.4 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 2.4 mg (one tablet in each dose will be a placebo tablet to maintain the blind) for up to 7 days.</description>
        </group>
        <group group_id="B2">
          <title>DB: Lofexidine HCl 3.2mg Dose</title>
          <description>Participants were randomized to receive 3.2 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 3.2 mg for up to 7 days.</description>
        </group>
        <group group_id="B3">
          <title>DB: Placebo</title>
          <description>Participants were randomized to receive placebo during the double-blind period of the study. Subjects will take 4 tablets QID for up to 7 days.&#xD;
Placebo: Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="229"/>
            <count group_id="B2" value="222"/>
            <count group_id="B3" value="151"/>
            <count group_id="B4" value="602"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="10.8"/>
                    <measurement group_id="B2" value="35" spread="10.5"/>
                    <measurement group_id="B3" value="36" spread="11.9"/>
                    <measurement group_id="B4" value="35" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="175"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="519"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="444"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.0" spread="16.88"/>
                    <measurement group_id="B2" value="76.1" spread="16.59"/>
                    <measurement group_id="B3" value="76.0" spread="14.94"/>
                    <measurement group_id="B4" value="76.1" spread="16.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (kg/m^2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.1" spread="4.71"/>
                    <measurement group_id="B2" value="25.1" spread="5.32"/>
                    <measurement group_id="B3" value="25.1" spread="4.63"/>
                    <measurement group_id="B4" value="25.1" spread="4.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference Between the Overall Means From Short Opiate Withdrawal Scale of Gossop (SOWS-Gossop) Scores</title>
        <description>The SOWS-Gossop was completed by the mITT population subject at baseline, once daily at 3.5 hours after the first dose of the study medication on Days 1 to 7. It consists of 10 items that are scored on a 4-point scale; 0=none, 1=mild, 2=moderate, and 3=severe. The overall score is the simple sum of the 10-item scores (minimum overall score of 0, maximum score of 30). Higher individual scores on the scale indicate greater symptom severity. However, as the outcome measure is a difference from placebo, a lower number indicates a better outcome.&#xD;
mITT population: all randomized subjects who received at least 1 dose of study medication</description>
        <time_frame>Days 1 through 7</time_frame>
        <population>mITT population Participants Analyzed does not match the Participant Flow because of missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>DB: Lofexidine HCl 2.4mg Dose</title>
            <description>Participants were randomized to receive 2.4 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 2.4 mg (one tablet in each dose will be a placebo tablet to maintain the blind) for up to 7 days.</description>
          </group>
          <group group_id="O2">
            <title>DB: Lofexidine HCl 3.2mg Dose</title>
            <description>Participants were randomized to receive 3.2 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 3.2 mg for up to 7 days.</description>
          </group>
          <group group_id="O3">
            <title>DB: Placebo</title>
            <description>Participants were randomized to receive placebo during the double-blind period of the study. Subjects will take 4 tablets QID for up to 7 days.&#xD;
Placebo: Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between the Overall Means From Short Opiate Withdrawal Scale of Gossop (SOWS-Gossop) Scores</title>
          <description>The SOWS-Gossop was completed by the mITT population subject at baseline, once daily at 3.5 hours after the first dose of the study medication on Days 1 to 7. It consists of 10 items that are scored on a 4-point scale; 0=none, 1=mild, 2=moderate, and 3=severe. The overall score is the simple sum of the 10-item scores (minimum overall score of 0, maximum score of 30). Higher individual scores on the scale indicate greater symptom severity. However, as the outcome measure is a difference from placebo, a lower number indicates a better outcome.&#xD;
mITT population: all randomized subjects who received at least 1 dose of study medication</description>
          <population>mITT population Participants Analyzed does not match the Participant Flow because of missing data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="227"/>
                    <count group_id="O2" value="220"/>
                    <count group_id="O3" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="6.00"/>
                    <measurement group_id="O2" value="7.6" spread="6.75"/>
                    <measurement group_id="O3" value="9.4" spread="6.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="183"/>
                    <count group_id="O3" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="6.83"/>
                    <measurement group_id="O2" value="9.9" spread="7.38"/>
                    <measurement group_id="O3" value="13.9" spread="8.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="154"/>
                    <count group_id="O2" value="139"/>
                    <count group_id="O3" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="5.53"/>
                    <measurement group_id="O2" value="7.4" spread="6.34"/>
                    <measurement group_id="O3" value="10.9" spread="6.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="5.32"/>
                    <measurement group_id="O2" value="5.5" spread="5.36"/>
                    <measurement group_id="O3" value="9.2" spread="6.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="4.60"/>
                    <measurement group_id="O2" value="4.5" spread="4.96"/>
                    <measurement group_id="O3" value="6.4" spread="5.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="3.97"/>
                    <measurement group_id="O2" value="3.2" spread="4.10"/>
                    <measurement group_id="O3" value="4.4" spread="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="3.45"/>
                    <measurement group_id="O2" value="2.3" spread="3.23"/>
                    <measurement group_id="O3" value="2.7" spread="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Due to the amount of missing data a pattern mixture model (or Jump to Reference) was utilized. The SOWS-Gossop total scores were log transformed. Each subjects available data Days 1-7 were included. The datasets created by the pattern mixture model were analyzed using a Mixed Model Repeated Measures model that included fixed effects for treatment group, baseline, sex, study day (1-7), and treatment group-by-day interaction. The overall estimate for each treatment group were compared.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0166</p_value>
            <method>Pattern Mixture Model</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Due to the amount of missing data a pattern mixture model (or Jump to Reference) was utilized. The SOWS-Gossop total scores were log transformed. Each subjects available data Days 1-7 were included. The datasets created by the pattern mixture model were analyzed using a Mixed Model Repeated Measures model that included fixed effects for treatment group, baseline, sex, study day (1-7), and treatment group-by-day interaction. The overall estimate for each treatment group were compared.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0033</p_value>
            <method>Pattern Mixture Model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Completion Status</title>
        <description>The percentage of subjects in each treatment arm who receive at least one dose of study medication on Day 7 and complete the 3.5 hour post-dose SOWS-Gossop assessment on Day 7.</description>
        <time_frame>Day 7</time_frame>
        <population>The percentage of subjects in each treatment arm who complete the double-blind phase of the study (defined as those who receive at least one dose of study medication on Day 7 and complete the 3.5 hour post-dose SOWS-Gossop assessment on Day 7).</population>
        <group_list>
          <group group_id="O1">
            <title>DB: Lofexidine HCl 2.4mg Dose</title>
            <description>Participants were randomized to receive 2.4 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 2.4 mg (one tablet in each dose will be a placebo tablet to maintain the blind) for up to 7 days.</description>
          </group>
          <group group_id="O2">
            <title>DB: Lofexidine HCl 3.2mg Dose</title>
            <description>Participants were randomized to receive 3.2 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 3.2 mg for up to 7 days.</description>
          </group>
          <group group_id="O3">
            <title>DB: Placebo</title>
            <description>Participants were randomized to receive placebo during the double-blind period of the study. Subjects will take 4 tablets QID for up to 7 days.&#xD;
Placebo: Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Completion Status</title>
          <description>The percentage of subjects in each treatment arm who receive at least one dose of study medication on Day 7 and complete the 3.5 hour post-dose SOWS-Gossop assessment on Day 7.</description>
          <population>The percentage of subjects in each treatment arm who complete the double-blind phase of the study (defined as those who receive at least one dose of study medication on Day 7 and complete the 3.5 hour post-dose SOWS-Gossop assessment on Day 7).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes/Complete</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No/Did Not Complete</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="134"/>
                    <measurement group_id="O3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion (14 Days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DB: Lofexidine HCl 2.4mg Dose</title>
          <description>Participants were randomized to receive 2.4 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 2.4 mg (one tablet in each dose will be a placebo tablet to maintain the blind) for up to 7 days.</description>
        </group>
        <group group_id="E2">
          <title>DB: Lofexidine HCl 3.2mg Dose</title>
          <description>Participants were randomized to receive 3.2 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 3.2 mg for up to 7 days.</description>
        </group>
        <group group_id="E3">
          <title>DB: Placebo</title>
          <description>Participants were randomized to receive placebo during the double-blind period of the study. Subjects will take 4 tablets QID for up to 7 days.&#xD;
Placebo: Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.</description>
        </group>
        <group group_id="E4">
          <title>OL: All Lofexidine HCl</title>
          <description>Participants were given the option to receive lofexidine HCl tablets for up to 7 additional days, following the double blind period. Dosing regimens are at the discretion of the Investigator, but total daily dose will not exceed 3.2 mg.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="216" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="211" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="134" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Affairs</name_or_title>
      <organization>US WorldMeds</organization>
      <phone>1-888-900-8796</phone>
      <email>medinfo@usworldmeds.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

